{
    "clinical_study": {
        "@rank": "41678", 
        "arm_group": {
            "arm_group_label": "Single Arm: ATS907", 
            "arm_group_type": "Experimental", 
            "description": "Single-cohort, dose-escalation"
        }, 
        "brief_summary": {
            "textblock": "This single-site, dose-escalation study will evaluate safety and tolerability of increasing\n      concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular\n      Hypertension"
        }, 
        "brief_title": "ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or greater\n\n          -  Diagnosis of open angle glaucoma or ocular hypertension in both eyes\n\n          -  Corrected visual acuity in each eye +1.0 logMAR or better by Early Treatment Diabetic\n             Retinopathy Study (EDTRS) in each eye (equivalent to 20/200)\n\n          -  Must be willing to discontinue the use of all ocular hypotensive medications in both\n             eyes prior to and during the entire course of the study\n\n        Exclusion Criteria:\n\n        Ophthalmic (in either eye):\n\n          -  Glaucoma: pseudoexfoliation, steroid induced, pigment dispersion glaucoma, and or\n             history of angle closure. Previous glaucoma intraocular surgery or glaucoma laser\n             procedures in study eye(s). Refractive surgery in study eye\n\n          -  Cataract surgery and or other intraocular surgery within one month prior to Screening\n             in either eye\n\n          -  History within 3 months prior to Screening of clinically significant moderate or\n             severe chronic or active ocular infection, inflammation, blepharitis, dermatitis,\n             uveitis or conjunctivitis\n\n          -  Clinically significant corneal dystrophy, epithelial and or endothelial disease,\n             corneal irregularities and or scarring such that reliable applanation tonometry would\n             prevented\n\n          -  Contact lens wear during the duration of the study\n\n          -  Clinically significant ocular disease (e.g., diabetic retinopathy, macular\n             degeneration,  or uveitis) which might interfere or progress during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668524", 
            "org_study_id": "ATS907-205"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm: ATS907", 
            "description": "Single dose of each of three increasing concentrations", 
            "intervention_name": "ATS907", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 5, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Artesia", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90701"
                }, 
                "name": "Sall Research Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2a Open-Label, Dose-ranging Study of the Safety and Tolerability of ATS907 in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluate local ocular safety and tolerability: change from baseline in ocular tolerability signs and symptoms (hyperemia, irritation, pain, tearing) using ocular tolerability and hyperemia grading scales; and change from baseline for vital signs", 
            "safety_issue": "Yes", 
            "time_frame": "3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Altheos, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Altheos, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}